UGT2B15: A Potential Drug Target for Glucuronosyl Transferase

Target Name: UGT2B15

NCBI ID: G7366

UGT2B15

UGT2B15: A Potential Drug Target for Glucuronosyl Transferase

UGT2B15 (UDP-glucuronosyltransferase UGT2B15) is a gene that encodes a protein known as UGT2B15. UGT2B15 is a member of the UGT family of enzymes that are involved in the detoxification and metabolization of drugs and other substances. The function of UGT2B15 is to catalyze the transfer of the glucose group from the urea nitrogen base to the glucuronosyl group of the detoxified drug.

UTG2B15 is a widely expressed gene that is found in all organisms, including humans. It is primarily expressed in the liver, where it is involved in the detoxification and metabolism of a wide variety of drugs. UGT2B15 is often used as a drug target or biomarker because of its unique expression patterns and its ability to interact with many different types of drugs.

One of the unique features of UGT2B15 is its ability to transfer the glucose group from the urea nitrogen base to the glucuronosyl group. This transfer reaction is critical for the detoxification of many types of drugs, including many chemotherapy drugs, which are often metabolized by UGT2B15. The ability of UGT2B15 to transfer the glucose group from the urea nitrogen base to the glucuronosyl group also makes it a potential target for drugs that are designed to inhibit its activity.

In addition to its role in drug detoxification, UGT2B15 is also involved in the metabolism of many other substances, including toxins and other substances that are produced by the body. This makes it an attractive target for drugs that are designed to modify the levels of these substances in the body.

Another unique feature of UGT2B15 is its ability to be regulated by multiple factors, including drugs, nutrients, and environmental factors. This makes it an attractive target for drugs that are designed to modulate its activity and improve the effectiveness of drug treatments.

In conclusion, UGT2B15 is a gene that encodes a protein that is involved in the detoxification and metabolism of drugs and other substances. Its unique ability to transfer the glucose group from the urea nitrogen base to the glucuronosyl group makes it an attractive target for drugs that are designed to inhibit its activity or modulate its activity. Its ability to be regulated by multiple factors also makes it an attractive target for drugs that are designed to improve the effectiveness of drug treatments. Further research is needed to fully understand the role of UGT2B15 in the detoxification and metabolism of drugs and other substances.

Protein Name: UDP Glucuronosyltransferase Family 2 Member B15

Functions: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:7835232, PubMed:9295060, PubMed:16595710, PubMed:18719240, PubMed:23288867). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:7835232). Catalyzes the glucuronidation of endogenous steroid hormones such as androgens (testosterone, androsterone) and estrogens (estradiol, epiestradiol, estriol, catechol estrogens) (PubMed:7835232, PubMed:9295060, PubMed:16595710, PubMed:18719240, PubMed:23288867). Displays glucuronidation activity toward several classes of xenobiotic substrates, including phenolic compounds (eugenol, 4-nitrophenol, 4-hydroxybiphenyl) and phenylpropanoids (naringenin, coumarins) (PubMed:7835232). Catalyzes the glucuronidation of monoterpenoid alcohols such as borneol, menthol and isomenthol, a class of natural compounds used in essential oils (By similarity)

The "UGT2B15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT2B15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets